OVI 117Alternative Names: Derivative of FduMP/5-FU (OVI-117); L-117; L-nucleoside conjugate (OVI-117); OVI-117
Latest Information Update: 02 Jun 2016
At a glance
- Originator Genencor International; Lipitek International
- Developer OncoVista
- Class Antineoplastics; Drug conjugates; Nucleosides
- Mechanism of Action Thymidylate synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Colorectal cancer